Tech24 Deals Web Search

Search results

1. Results from the Tech24 Deals Content Network

2. Walmart launches private label insulin brand at steep ... - AOL

   www.aol.com/news/walmart-launches-private-label...

   Walmart's new private label brand, ReliOn NovoLog, includes analog insulin vials retailing $72.88 and a FlexPen selling for $85.88.

3. List of Walmart brands - Wikipedia

   en.wikipedia.org/wiki/List_of_Walmart_brands

   Sam's Choice, originally introduced as Sam's American Choice in 1991, is a retail brand in food and selected hard goods. Named after Sam Walton, founder of Walmart, Sam's Choice forms the premium tier of Walmart's two-tiered core corporate grocery branding strategy that also includes the larger Great Value brand of discount-priced staple items.

4. GLP-1 receptor agonist - Wikipedia

   en.wikipedia.org/wiki/GLP-1_receptor_agonist

   GLP-1 agonists were developed initially for type 2 diabetes. [5] The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonist or SGLT2 inhibitor as a first line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure.

5. Dipeptidyl peptidase-4 inhibitor - Wikipedia

   en.wikipedia.org/wiki/Dipeptidyl_peptidase-4...

   Dipeptidyl peptidase-4 inhibitor. Inhibitors of dipeptidyl peptidase 4 ( DPP-4 inhibitors or gliptins) are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2 . The first agent of the class – sitagliptin – was approved by the FDA in 2006.

6. Abbott says market overestimating sales hit from new diabetes ...

   www.aol.com/abbott-profit-beats-strong-sales...

   Abbott Laboratories said the market was overestimating the hit to sales of its glucose monitoring products from growing popularity of new diabetes drugs, adding the treatments could end up ...

7. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   SGLT2 inhibitors (also called gliflozins or flozins) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional units of the kidney ), unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa. The foremost metabolic effect of this is to inhibit reabsorption of glucose in the ...